A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
PatientsLikeMe is continuing to expand its business into new areas. Having struck its first broad R&D collaboration with a biopharma earlier this year, the online patient network has now given Actelion access to its community to create a new health outcome measure for a rare cancer.
Ventana and Quintiles are partnering up to provide companion diagnostic testing services in China for early clinical trials. China is among a few countries that requires patient samples used in clinical trials to be tested domestically for inclusion in the country's approval process.
The technology going into the device, called Rapid Evaporative Ionization Mass Spectrometry, by the Waters Corporation, is a move that one of the developers hopes will give the project new momentum.
Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.
The FDA panel convened to discuss the risk of upstaging uterine sarcoma cancer via minimally invasive laparoscopic power morcellation during uterine surgery for fibroids recommended upgrading the labeling of power morcellators and ensuring that patients are made aware of the risk prior to surgery, among other measures.
Panelists were concerned about the lack of data on the prevalence of uterine sarcoma among women undergoing hysterectomy or myomectomy surgeries during the first day of the FDA panel on the risks of upstaging uterine cancer via minimally invasive laparoscopic power morcellation during uterine surgery for fibroids.
Researchers at The Ohio State University have found that to treat brain cancer and other solid tumors, a low dose of the proteasome inhibitor bortezomib improves oncolytic viruses' ability to kill cancer cells.
Researchers at UC Santa Barbara have concocted a new type of silver nanoparticle designed to deliver cancer drugs that can also dissolve and become inactive if it doesn't reach the tumor. The innovation solves some safety issues associated with nanotechnology and reduces side effects from the cancer drugs themselves, the scientists say.